Search

OBJECTIVE: Fibromyalgia (FM) is a clinical syndrome characterized by prominent physical and psychological impairment and widespread pain on both sides of the body, above and below the waist, and along the axial skeleton. It often causes sleep difficulties, memory impairment, mood changes, irritable bowel syndrome, and fatigue. Our study aimed to investigate the relationship between FM and prolidase (peptidase D) and histone H3 protein levels by comparing a patient group with a healthy control group. PATIENTS AND METHODS: In total, 176 people were examined in our study, 88 of whom were healthy and 88 of whom had FM. Serum level was measured by ELISA. Then the results were analyzed using SPSS. All p < 0.05 were considered statistically significant. RESULTS: A significant increase in the levels of prolidase was observed in the patient group compared with the control group (6.28-4.68, p

Background: Breast cancer is a leading cause of death in women worldwide. Genetic polymorphisms have been reported to be important etiological factors. Murine double minute 2 (MDM2) T309G interacts with p53 and mutations in p53 are present in approximately 50% of all cancers. However, it has been reported that effect of the polymorphism on breast cancer risk may vary in different populations. Here, we therefore investigated whether there is an association between MDM2 T309G (rs2279744) polymorphism and breast cancer in a Turkish population. Materials and Methods: We analysed 110 patients with breast cancer and 138 matched? controls. For genotyping, polymerase chain reaction and restriction length fragment polymorphism methods were used. Results: A significant difference was observed between case and control groups with regard to the distribution of the MDM2 T309G polymorphism (p

WOS: 000388616700013, PubMed ID: 25926273, This study was aimed at determining the acute and chronic toxic effects of cypermethrin, propetamphos, and combined cypermethrin and propetamphos. Four groups, each comprising 10 animals, were established for the acute (a) and chronic (b) toxicity trials, and in total, 80 male Wistar albino rats were used. In the acute toxicity trial, the first group was maintained for control purposes, and groups 2a, 3a, and 4a were administered only once with 80 mg/kg.bw of cypermethrin, 25 mg/kg.bw of propetamphos and 80 mg/kg.bw of cypermethrin combined with 25 mg/kg.bw of propetamphos, respectively, by gavage directly into the stomach. In the chronic toxicity trial, the first group was also maintained for control purposes, while groups 2b, 3b, and 4b were administered daily with 12 mg/kg.bw of cypermethrin, 4 mg/kg.bw of propetamphos, and 12 mg/kg.bw of cypermethrin combined with 4 mg/kg.bw of propetamphos respectively, by gavage directly into the stomach for 60 days. Blood and tissue (liver, kidney, brain, spleen, and testis) samples were taken 24 h after pesticide administration in the acute toxicity trial and at the end of day 60 in the chronic toxicity trial. Oxidative stress (MDA, NO, SOD, CAT, GSH-Px, and G6PD) parameters, serum biochemical parameters (glucose, triglyceride, cholesterol, HDL, LDL, BUN, creatinine, AST, ALT, ALP, protein, and albumin) and hepatic drug-metabolizing parameters (CYP2E1, CYPB5, CYTC, GST, and GSH) were investigated in the samples. When administered either alone or in combination, both pesticides inhibited the antioxidant enzymes and increased MDA and NO levels. For the drug-metabolizing parameters investigated, particularly in the chronic period, either increase (CYP2E1, CYPB5, and CYTC) or decrease (GST and GSH) was observed. Furthermore, some negative changes were detected in the serum biochemical parameters. In result, cypermethrin and propetamphos combinations and long-term exposure to these combinations produced a greater toxic effect than the administration of these insecticides alone. (C) 2015 Wiley Periodicals, Inc., Erciyes University [TSA-091132], Contract grant sponsor: Research Fund of Erciyes University.; Contract grant number: TSA-091132.

Amaç: Akciğer kanseri dünya genelinde kansere bağlıölümlerin önde gelen nedenidir. Tanısal cihazlar ve teknolojik gelişmelerebağlı tedavi seçeneklerinde ilerlemeye rağmen, akciğer kanseri hastalarındagenel mortalite oranı hala yüksektir. Akciğer kanseri hastalarında sağkalımoranları, özellikle ilerlemiş inoperabl hastalıkta, immunoterapi gibi yenitedavi seçeneklerine rağmen düşüktür. p53, kanser hastalarının %60-70’inde mutasyonauğramaktadır ve bu nedenle son zamanlarda yapılan çalışmalar göstermektedir ki,serum anti-p53 antikorunun, over, özefagus, meme ve akciğer kanseri gibi bazıkanser türlerinin dedekte edilmesinde biyobelirteç olarak dikkate alınabilir.Bu çalışmada, akciğer kanseri hastalarında, serum anti-p53antikor düzeylerinintanısal ve prognostik önemini araştırmayı amaçladık.Yöntem: Çalışmayaakciğer kanseri (AK) tanısı nedeniyle evreleme için 18F-FDG-PET / BTgörüntüleme amacı ile bölümümüze sevk edilen hastalar, toraks BT’sinde şüphelipulmoner nodül olup, patolojik FDG birikimi göstermeyen hastalar (NAPN= Non-avid FDG gösterenpulmoner nodül) ve sağlıklı gönüllüler dahil edildi. Serum anti-p53antikordüzeyleri tüm hastalarda ELISA yöntemi ile ölçüldü. Hastaların ortalama takipsüresi 13 ay idi.Bulgular: Çalışmaya toplam 65 AK hastası (58E/7K), 47 NAPNhastası (20E/27K) ve 34 sağlıklı gönüllü (26E /8K) dahil edildi. Ortalama serumanti-p53antikor seviyeleri AK hastalarında 3.4ng/mL, NAPN hastalarında 3.77ng/mL, sağlıklı gönüllülerde 3.07 ng/ mL idi. AK hastaları ile NAPN hastaları arasındaserum anti-p53antikor düzeyi için istatistiksel olarak anlamlı fark yoktu (p =0.678). Hatta, hastalarve sağlıklı gönüllüler arasında serum anti-p53Ab düzeyi için istatistikselolarak anlamlı fark yoktu (p = 0.377). Hastaların iki yıllık medyan sağkalımı14 aydı. Hastalarınsağkalım hızında, serum anti-p53Ab düzeyinin > 3.4 ng/ mL veya ≤3.4 ng/ mL olmasının herhangi bir etkisininolmadığı bulundu (p = 0.652).Sonuç: Anti-p53antikoru,karsinogeneziste çok önemli olmasına rağmen, serum anti-p53antikor düzeyininakciğer kanseri tanısında ve sağkalım oranlarında tek başına önemli olmadığını düşünüyoruz. Karsinogenezistebirden fazla faktör vardır ve bu durumun nedeni olabilir. Akciğer kanserihastalarının teşhisi için serum anti-p53antikor düzeylerinin bilinen bir katofdeğeri yoktur. Bu nedenle, buantikorun tümör spesifikliği olmadığını ve serum anti-p53antikor düzeyininakciğer kanseri taraması için uygun olmadığını düşünüyoruz., Objective: Lung cancer is the leading causeof cancer-related deaths worldwide. Despite advancement in diagnostic tools andtreatment options with technological developments, overall mortality rates inlung cancer patients remains high. Survival rates in lung cancer patients islow especially in advanced diseased inoperable patients in spite of newtreatment options like immunotherapy. p53 is mutated in 60-70% of cancerpatients and for this reason has been extensively studied recent researches suggest that serumanti-p53Ab can be considered as biomarkers to detect many types of cancers; asovarian cancer, esophageal cancer, breast cancer and lung cancer. In this studywe aimed that are there any diagnostic and prognostic importance of serumanti-p53Ab levels in lung cancer patients.Method: Patients were included who werereferred to our department with the purpose of 18F-FDG-PET/CTimaging for staging due to lung cancer diagnosis (LC) and patients who wereperformed 18F-FDG-PET/CT for diagnosis in the cause of the suspectedpulmonary nodule in thorax CT but not detected pathologic FDG accumulation(NAPN=pulmonary nodule with non-avid-FDG) and healthy volunteers. Serumanti-p53Ab levels were measured with ELISA method in the all patients. Meanfollow up time of patients were 13 months.Results: A total of 65 LC patients(58M/7F), 47 patients with NAPN (20M/27F), and a total of 34 healthy volunteers(26M/8F) were included in this study. Median serum anti-p53Ab levels are3.4ng/mL in LC patients, 3.77ng/mL in NAPN patients, 3.07ng/mL in healthyvolunteers. There is no statistically significant difference for serumanti-p53Ab level between LC patients and NAPN patients (p=0.678). Moreover there is no statistically significant differencefor serum anti-p53Ab level between patients and healthy volunteers (p=0.377). Two-year median survival ofpatients was 14 month. It has been found that there is no effect of serumanti-p53Ab level whether >3.4 or ≤3.4 on the patient survival rate (p=0.652).Conclusions: Even thoughanti-p53Ab is very important in carcinogenesis, we think that serum anti-p53Ablevel by itself is not important in lung cancer diagnosis and survival rates.There are multiple factors in carcinogenesis and this may be the reason of thissituation. There is no known cut off value of serum anti-p53 Ab levels fordiagnosis of lung cancer patients. Therefore we think that this antibody is nottumor spesific and serum anti-p53 Ab level measurement is not appropriate forlung cancer screening.